Medicine for treating rheumatoid arthritis
Through the synergistic effect of the JAK3 inhibitor tofatinib with resylene leverin, puerarin and danpiol, the existing problems of low efficiency and major side effects of rheumatoid arthritis treatment are solved, and more efficient arthritis treatment effect is achieved and lower side effects significantly improve patients' clinical symptoms and laboratory indicators.
Patent Information
- Application Number
- CN202411317224.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-20
- Publication Date
- 2024-11-08
AI Technical Summary
The existing treatment methods for rheumatoid arthritis are inefficient and have great side effects, making it difficult to effectively inhibit the JAK/STAT signal transduction pathway, resulting in poor treatment effect.
The synergistic effect of JAK3 inhibitor tofatinib and the combined synergists resylene leretinol, puerarin and dansol is used to improve the therapeutic effect of the drug by mixing different proportions, and it is introduced into the body through various dosage forms to improve the drug bioavailability.
It significantly improves the treatment effect of rheumatoid arthritis, reduces the side effects of drugs on the body, and significantly improves the patients' joint symptoms and laboratory examination indicators.
Smart Images

Figure BDA0005052552820000051
Abstract
Description
Technical Field
[0001] The invention provides a medicine for treating rheumatoid arthritis and belongs to the technical field of medicine. Background Art
[0002] Rheumatoid arthritis, also known as rheumatoid arthritis (RA), is a chronic systemic inflammatory disease with an unknown etiology. It is currently recognized that rheumatoid arthritis is an autoimmune disease. It may be related to differences in endocrine, metabolism, nutrition, geography, occupation, psychology and social environment, bacterial and viral infections and genetic factors. It is an autoimmune inflammatory disease with chronic, symmetrical, polysynovial arthritis and extra-articular lesions as the main clinical manifestations. The disease is prone to small joints such as hands, wrists, and feet, with repeated attacks and symmetrical distribution. In the early stage, there are joint redness, swelling, heat, pain and dysfunction. In the late stage, the joints may have varying degrees of stiffness and deformity, accompanied by atrophy of bones and skeletal muscles. If not treated formally, it is very easy to cause disability.
[0003] In recent years, studies have shown that the Janus kinase (JAK) / signal transducer and activator of transcription (STAT) signal transduction pathway is a new target for the treatment of RA. Summary of the invention
[0004] In view of this, the purpose of the present invention is to provide a drug for treating rheumatoid arthritis containing a JAK3 inhibitor. The present invention utilizes a composite synergist and a JAK3 inhibitor to synergize, so that the drug can quickly treat rheumatoid arthritis while reducing the side effects of the drug on the body.
[0005] The present invention is specifically implemented by adopting the following technical solutions:
[0006] A drug for treating rheumatoid arthritis, comprising a JAK3 inhibitor and a composite synergist; the composite synergist is a mixture of resveratrol, puerarin and paeonol; the JAK3 inhibitor is tofacitinib.
[0007] Preferably, the mass ratio of the JAK3 inhibitor to the synergist is 3 to 5:1.
[0008] Preferably, the mass ratio of resveratrol, puerarin and paeonol is 1:2-6:3-4.
[0009] Preferably, the mass ratio of resveratrol, puerarin and paeonol is 1:5:3.
[0010] Preferably, the mass ratio of resveratrol, puerarin and paeonol is 1:2:4.
[0011] Preferably, the mass ratio of resveratrol, puerarin and paeonol is 1:3:3.
[0012] Preferably, the mass ratio of resveratrol, puerarin and paeonol is 1:6:4.
[0013] Preferably, the mass ratio of resveratrol, puerarin and paeonol is 1:4:3.
[0014] Preferably, the mass ratio of resveratrol, puerarin and paeonol is 1:4:4.
[0015] The drugs for preventing and / or treating rheumatoid arthritis and the drugs for inhibiting the proliferation of synovial cells of rheumatoid arthritis in the present invention can be introduced into the body such as muscle, intradermal, subcutaneous, intravenous, mucosal tissue by injection, spraying, penetration, absorption, physical or chemical mediation; or introduced into the body after being mixed or wrapped with other substances. According to medical needs, one or more pharmaceutically acceptable carriers can also be added to the drugs of the present invention. The carriers include conventional diluents, excipients, fillers, adhesives, wetting agents, disintegrants, absorption promoters, surfactants, adsorption carriers, lubricants, etc. in the pharmaceutical field. The drugs of the present invention can be prepared into various forms such as injection, tablets, powders, granules, capsules, oral liquids, ointments, creams, etc. The drugs in the above various dosage forms can be prepared according to conventional methods in the pharmaceutical field.
[0016] Compared with the prior art, the present invention has the following technical effects:
[0017] The present invention provides a drug for treating rheumatoid arthritis containing a JAK3 inhibitor, specifically using resveratrol, puerarin and paeonol as synergists to synergize with the JAK3 inhibitor, thereby improving the therapeutic effect of the drug on rheumatoid arthritis. DETAILED DESCRIPTION
[0018] In order to make the purpose, technical scheme and advantages of the present invention clearer, the preferred embodiments of the present invention are further described in detail in conjunction with the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0019] Example 1
[0020] A drug for treating rheumatoid arthritis is prepared by mixing a JAK3 inhibitor and a composite enhancer at a mass ratio of 5:1, wherein the composite enhancer is a mixture of resveratrol, puerarin and paeonol at a mass ratio of 1:5:3.
[0021] Example 2
[0022] A drug for treating rheumatoid arthritis is prepared by mixing a JAK3 inhibitor and a composite synergist at a mass ratio of 5:1, wherein the composite synergist is a mixture of resveratrol, puerarin and paeonol at a mass ratio of 1:2:4.
[0023] Example 3
[0024] A drug for treating rheumatoid arthritis is prepared by mixing a JAK3 inhibitor and a composite synergist at a mass ratio of 5:1, wherein the composite synergist is a mixture of resveratrol, puerarin and paeonol at a mass ratio of 1:3:3.
[0025] Example 4
[0026] A drug for treating rheumatoid arthritis is prepared by mixing a JAK3 inhibitor and a composite synergist at a mass ratio of 5:1, wherein the composite synergist is a mixture of resveratrol, puerarin and paeonol at a mass ratio of 1:6:4.
[0027] Example 5
[0028] A drug for treating rheumatoid arthritis is prepared by mixing a JAK3 inhibitor and a composite enhancer at a mass ratio of 5:1, wherein the composite enhancer is a mixture of resveratrol, puerarin and paeonol at a mass ratio of 1:4:3.
[0029] Example 6
[0030] A drug for treating rheumatoid arthritis is prepared by mixing a JAK3 inhibitor and a composite enhancer at a mass ratio of 5:1, wherein the composite enhancer is a mixture of resveratrol, puerarin and paeonol at a mass ratio of 1:4:4.
[0031] Example 7
[0032] A drug for treating rheumatoid arthritis is prepared by mixing a JAK3 inhibitor and a composite synergist at a mass ratio of 3:1, wherein the composite synergist is a mixture of resveratrol, puerarin and paeonol at a mass ratio of 1:5:3.
[0033] 1. Animal experiments
[0034] 100 μl of modeling agent 1 was injected intradermally at 1-2 cm from the base of the mouse tail, and the control group was injected with an equal volume of complete Freund's adjuvant. The day of injection was marked as day 0. 21 days later, the second modeling was performed with an equal volume of modeling agent 2, and the control group was injected with an equal volume of incomplete adjuvant. After another week (i.e. 28 days), the mouse hind paws began to become red and swollen, and the movements became slow, indicating that the RA animal model was successfully established. The symptoms can last for 2 months. Among them, the bovine type II collagen acetic acid solution and the complete Freund's adjuvant in equal volumes were fully mixed and completely emulsified (emulsified at 4°C), and were marked as modeling agent 1; the bovine type II collagen acetic acid solution and the incomplete Freund's adjuvant in equal volumes were fully mixed and completely emulsified, and were marked as modeling agent 2;
[0035] After the second modeling, the mental state, appetite and activity of the mice were observed; the severity of arthritis was evaluated by the arthritis index starting from the second modeling (21st day), measured every 3 days, and the clinical arthritis scoring criteria were as follows: no symptoms-0 points, obvious swelling and redness of one toe-1 point, mild swelling of the limbs or swelling of more than two toes-2 points, obvious swelling and erythema of the limbs-3 points, severe swelling and erythema of the limbs, and ankylosis-4 points.
[0036] The mice developed severe swelling and erythema of the limbs, that is, the model was successfully established. The mice with successful modeling were randomly divided into 9 groups (blank group, control group and 1#~7# experimental group), 10 mice in each group, and the breeding environment was 22±1°C, 12h light / 12h dark cycle. All operations were strictly carried out in accordance with the national health and hygiene guidelines. The drugs prepared in Examples 1 to 7 were dispersed in normal saline to obtain 1#~7# agents, and the mice in the 1#~7# experimental groups were injected respectively. Tofacitinib was dispersed in normal saline to obtain 0# agent, which was injected into the control group mice. Among them, the blank group was injected with normal saline only. The above injection dosage was 0.2mg / Kg / day (calculated by dry matter mass). After a period of administration, the arthritis index of the mice was scored, as shown in Table 1.
[0037] Table 1 Results of mouse arthritis index scoring
[0038] 7 days of medication 14 days of medication 30 days of medication 1# Experimental group 3 points 2 points 1 point 2# Experimental Group 3 points 2 points 1 point 3# Experimental group 3 points 2 points 1 point 4# Experimental group 3 points 2 points 1 point 5# Experimental group 3 points 2 points 1 point 6# Experimental group 3 points 2 points 1 point 7# Experimental group 3 points 2 points 1 point Control group 4 points 4 points 3 points Blank Group 4 points 4 points 4 points
[0039] 2. Clinical Trials
[0040] To verify the drug of the present invention, a clinical trial was conducted on 100 adult rheumatoid patients:
[0041] The above patients were randomly divided into a treatment group and a control group, wherein the treatment group was given the drug of the present invention, 3 mg each time, twice a day, for 2 months as a course of treatment, and the control group was given tofacitinib 3 mg, twice a day, for 2 months as a course of treatment.
[0042] The main observation items for clinical patients are as follows:
[0043] (1) Joint symptoms and signs: including joint pain, swelling, morning stiffness, deformity, etc.
[0044] (2) Systemic symptoms and signs.
[0045] (3) Tongue and pulse condition.
[0046] (4) Laboratory observation indicators: Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were used as observation indicators.
[0047] The efficacy evaluation criteria are as follows:
[0048] 1. Clinical control: The main symptoms and signs disappear, and all laboratory examination indicators return to normal.
[0049] 2. Significantly effective: The overall improvement rate of major symptoms and signs is ≥75%. Erythrocyte sedimentation rate and C-reactive protein are normal or significantly improved, or close to normal.
[0050] 3. Effective: The overall improvement rate of major symptoms and signs is ≥30%. Erythrocyte sedimentation rate and C-reactive protein have improved or not improved.
[0051] 4. Ineffective: The overall improvement rate of major symptoms and signs is less than 30%. ESR and C-reactive protein have no improvement.
[0052] The main symptoms and signs refer to the number of joint tenderness, the number of joint swelling, and the duration of morning stiffness. The overall improvement rate refers to the percentage of improvement of the above three items. The average value is calculated after adding them together.
[0053] Table 2 Indicators of the treatment group and the control group before treatment
[0054]
[0055]
[0056] Table 3 Indicators of the treatment group and the control group after treatment
[0057] Treatment Group Control group Number of swollen joints 7 18 Number of swollen joints 5 15 Number of joint pains 3 17 Number of joint tenderness 2 13 Morning stiffness 0 15 Poor flexion and extension 1 9 Fatigue 0 6 Dry mouth 0 5
[0058] It can be seen from Table 2 and Table 3 that the drug of the present invention has a very significant effect in treating rheumatoid arthritis clinically.
[0059] The embodiments described above are part of the embodiments of the present invention, rather than all of the embodiments. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention claimed for protection, but merely represents selected embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
Claims
1. A drug for treating rheumatoid arthritis, comprising a JAK3 inhibitor, characterized in that: It also includes a composite synergist; the composite synergist is a mixture of resveratrol, puerarin and paeonol; and the JAK3 inhibitor is tofacitinib.
2. The drug for treating rheumatoid arthritis according to claim 1, characterized in that: The mass ratio of the JAK3 inhibitor to the synergist is 3 to 5:
1.
3. The drug for treating rheumatoid arthritis according to claim 1, characterized in that: The mass ratio of resveratrol, puerarin and paeonol is 1:2-6:3-4.
4. The drug for treating rheumatoid arthritis according to claim 1, characterized in that: The mass ratio of resveratrol, puerarin and paeonol is 1:5:
3.
5. The drug for treating rheumatoid arthritis according to claim 1, characterized in that: The mass ratio of resveratrol, puerarin and paeonol is 1:2:
4.
6. The drug for treating rheumatoid arthritis according to claim 1, characterized in that: The mass ratio of resveratrol, puerarin and paeonol is 1:3:
3.
7. The drug for treating rheumatoid arthritis according to claim 1, characterized in that: The mass ratio of resveratrol, puerarin and paeonol is 1:6:
4.
8. The drug for treating rheumatoid arthritis according to claim 1, characterized in that: The mass ratio of resveratrol, puerarin and paeonol is 1:4:
3.
9. The drug for treating rheumatoid arthritis according to claim 1, characterized in that: The mass ratio of resveratrol, puerarin and paeonol is 1:4:4.
